API

Insulin Isophane/NPH (50%) + Human Insulin/Soluble Insulin (50%)

Drug classification

Antidiabetic agent; biphasic insulin preparation (intermediate-acting and short-acting human insulin).

Dosage form

Sterile suspension for injection in a vial or cartridge for subcutaneous use.

API strength per dosage

Dose

Insugen 50/50 dosing is individualized based on blood glucose monitoring and clinical response. It is typically administered subcutaneously before meals. No fixed dose; adjust in adults and children as needed. In renal or hepatic impairment, insulin requirements may decrease; monitor closely and titrate to avoid hypoglycemia. Always follow prescriber instructions and local guidelines.

Mechanism of action

Insugen 50/50 contains 50% soluble human insulin (rapid-acting) and 50% isophane insulin (NPH, intermediate-acting). Both bind to insulin receptors (tyrosine kinase receptors) on target cells, promoting glucose uptake, glycogen synthesis, and inhibiting hepatic glucose production, thereby lowering blood glucose levels.

Indications

Diabetes

Side effects

Hypoglycemia low blood glucose level Injection site reactions pain swelling redness Weight gain

Pregnancy category

Human insulin products are considered safe in pregnancy; use is recommended to maintain optimal glycemic control, as insulin does not cross the placenta.

Precautions

Monitor blood glucose regularly, risk of hypoglycemia, adjust dose in renal/hepatic impairment, rotate injection sites, monitor for allergic reactions, caution in elderly, monitor potassium levels, avoid abrupt discontinuation, assess for drug interactions, educate on recognition and management of hypoglycemia, monitor for lipodystrophy.

Contraindications

Hypersensitivity to insulin or excipients, hypoglycemia, episodes of hypokalemia, not for intravenous administration, not for treatment of diabetic ketoacidosis, not for use in insulin pump therapy.